Table 2.
Ongoing clinical trials evaluating PARPi in combination with chemo-and radio-therapy in HER2 negative BC
| PARP inhibitor | Phase | Study population/ tumor type | Treatment | NCT |
|---|---|---|---|---|
| Olaparib | II/III | TNBC and/or gBRCA BC | Olaparib + paclitaxel + carboplatin | NCT03150576 |
| Olaparib | I | TNBC and advanced ovarian cancer | Olaparib + paclitaxel + carboplatin | NCT00516724 |
| Olaparib | I | Advanced HER2 negative BRCA1/2 mutated BC | Olaparib+carboplatin followed by Olaparib monotherapy vs Capecitabine | NCT02418624 |
| Olaparib | I | Inflammatory, loco-regionally advanced or metastatic TNBC or patient with operated TNBC with residual disease | Olaparib+ radiation therapy | NCT03109080 |
| Olparib | I | Locally Advanced Malignant Neoplasm, Inflammatory BC, TNBC | Olaparib+ radiation therapy | NCT02227082 |
| Veliparib | III | Metastatic HER2 negative or locally advanced unresectable BRCA-associated BC | Veliparib+ carboplatin+ paclitaxel | NCT02163694 |
| Veliparib | I | BC | Veliparib+radiation therapy | NCT01618357 |
| Rucaparib | II | Patients with invasive TNBC or ER/PR+, HER2 negative with known BRCA1/2 mutations | Rucaparib+ cisplatin | NCT01074970 |